Eiger Doses First Patient in Phase 2 Trial of PAH Therapy Candidate Bestatin
News, Pulmonary Hypertension
Eiger BioPharmaceuticals has dosed the first patient in its Phase 2 LIBERTY study with the company’s product candidate ubenimex (Bestatin). The trial will assess Bestatin’s effects when added to standard of care treatment in people ... Read more